Analysts Offer Predictions for Atea Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for Atea Pharmaceuticals in a research report issued to clients and investors on Monday, February 5th. Leerink Partnrs analyst R. Ruiz anticipates that the company will earn ($0.66) per share for the quarter. The consensus estimate […]

Related Keywords

Dwayne Foster ,Andrea Corcoran ,Leerink Partnrs ,Atea Pharmaceuticals Trading ,Blackrock Inc ,Nasdaq ,News Ratings For Atea Pharmaceuticals Daily ,Insider Activity At Atea Pharmaceuticals ,Advisor Group Holdings Inc ,Metlife Investment Management ,Jpmorgan Chase Co ,Atea Pharmaceuticals ,Institutional Trading Of Atea Pharmaceuticals ,Atea Pharmaceuticals Inc ,Securities Exchange Commission ,Envestnet Asset Management Inc ,Free Report ,Atea Pharmaceutical ,Get Free Report ,Exchange Commission ,Asset Management ,Group Holdings ,Life Investment Management ,Atea Pharmaceuticals Daily ,Nasdaq Avir ,Tavir ,Medical ,Earnings Estimates ,